Green Thumb Industries (GTBIF) Non-Current Debt (2019 - 2026)
Green Thumb Industries (GTBIF) posted Non-Current Debt of $266.3 million for Q1 2026, up 17.64% on a QoQ basis from $226.4 million in Q4 2025, and up 86.91% year-over-year from $142.5 million in Q1 2025.
Green Thumb Industries (GTBIF) Non-Current Debt (2019 - 2026) Analysis & Trends
Green Thumb Industries' Non-Current Debt history runs 8 years deep, the most recent figure standing at $266.3 million for Q1 2026.
- Quarterly Non-Current Debt rose 86.91% year-over-year to $266.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $266.3 million (up 86.91% YoY) and the FY2025 annual result came in at $226.4 million, down 11.2% from the prior year.
- Non-Current Debt was $266.3 million for Q1 2026 at Green Thumb Industries, up from $226.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $306.9 million in Q1 2024 and bottomed at $82.5 million in Q2 2024.
- A 5-year average of $247.6 million and a median of $255.0 million in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2024 — Non-Current Debt slumped 71.45% — and 2025, when it soared 203.05%.
- Green Thumb Industries' Non-Current Debt stood at $274.6 million in 2022, then gained by 11.25% to $305.5 million in 2023, then declined by 16.55% to $255.0 million in 2024, then fell by 11.2% to $226.4 million in 2025, then grew by 17.64% to $266.3 million in 2026.
- Business Quant data shows GTBIF's Non-Current Debt at $266.3 million in Q1 2026, $226.4 million in Q4 2025, and $230.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Green Thumb Industries | 1.63 Bn | 1.29 Bn | 143.65 Mn | 266.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 266.34 Mn |
| Dec 31, 2025 | 226.40 Mn |
| Sep 30, 2025 | 230.19 Mn |
| Jun 30, 2025 | 249.95 Mn |
| Mar 31, 2025 | 142.50 Mn |
| Dec 31, 2024 | 254.96 Mn |
| Sep 30, 2024 | 255.58 Mn |
| Jun 30, 2024 | 82.48 Mn |
| Mar 31, 2024 | 306.90 Mn |
| Dec 31, 2023 | 305.53 Mn |
| Sep 30, 2023 | 297.08 Mn |
| Jun 30, 2023 | 288.86 Mn |
| Mar 31, 2023 | 276.78 Mn |
| Dec 31, 2022 | 274.63 Mn |
| Sep 30, 2022 | 254.50 Mn |
| Jun 30, 2022 | 252.43 Mn |
| Mar 31, 2022 | 243.34 Mn |
| Dec 31, 2021 | 239.15 Mn |
| Sep 30, 2021 | 205.76 Mn |
| Jun 30, 2021 | 197.04 Mn |